Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $1.3 billion.

  • Ani Pharmaceuticals' Liabilities and Shareholders Equity rose 9.38% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 32.29%. This contributed to the annual value of $1.3 billion for FY2024, which is 41.94% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Liabilities and Shareholders Equity of $1.3 billion as of FY2024, which was up 41.94% from $904.4 million recorded in FY2023.
  • Ani Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.3 billion during FY2024, with a 5-year trough of $461.2 million in FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $904.4 million (2023), whereas its average is $982.7 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Liabilities and Shareholders Equity soared by 67.31% in 2021, and later dropped by 1.49% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $461.2 million in 2020, then surged by 67.31% to $771.6 million in 2021, then fell by 1.49% to $760.1 million in 2022, then climbed by 18.99% to $904.4 million in 2023, then skyrocketed by 41.94% to $1.3 billion in 2024.